ReachMD Healthcare Image
Media formats available:
  • Overview

    Chronic kidney disease-associated pruritus (CKD-aP) is a common and distressing symptom experienced by many patients with CKD, particularly those on hemodialysis. CKD-aP can significantly lower patients’ quality of life, disrupt sleep, and lead to skin damage. This condition remains underreported and under recognized, so your patients will thank you for joining our experts, Drs. Joel Topf and Kieran McCafferty, in their discussion. Tune in to find out how to implement an active screening approach and apply recent clinical trial data to modify your treatment plans and help alleviate itch symptoms in your patients with CKD.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. 

    Joel Topf, MD
    Clinical Assistant Professor
    Oakland University William Beaumont School of Medicine
    Rochester, Michigan

    Ownership Interest: AstraZeneca, Cara Therapeutics, OMIC, PROK, SERA, WBA
    Consulting Fees: AstraZeneca, Bayer, Cara Therapeutics, GSK, CSL Vifor

    Kieran McCafferty, MD
    Consultant Nephrologist
    Barts Health NHS Trust
    London, UK 

    Consulting Fees: AstraZeneca, Bayer, Napp, Oncacare, Pharmacosmos
    Contracted Research: AstraZeneca

    Reviewers/Content Planners/Authors:

    • Megan Clem has nothing to disclose.
    • Cindy Davidson has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • Hany Ibrahim, MD, has nothing to disclose.
    • Tim Person has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to: 

    • Evaluate the patient-reported outcome instruments used to capture the itch intensity and the itch-related quality of life in patients with advanced chronic kidney disease (CKD)
    • Select the most appropriate therapy to alleviate the symptom burden of CKD-associated pruritus based on clinical trial data in patients undergoing long-term hemodialysis
    • Demonstrate how to integrate selective kappa-opioid receptor agonist therapy in the treatment protocols for patients with advanced CKD
  • Target Audience

    This activity is designed to meet the educational needs of nephrologists and dermatologists.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    The American Medical Association has an agreement of mutual recognition of continuing medical education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 Credits to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at 

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for .25 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Our ultimate goal is to improve the care being delivered to patients, and our high-quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum.

  • Commercial Support

    This activity is supported by an independent educational grant from CSL Vifor.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments


We’re glad to see you’re enjoying Medtelligence…
but how about a more personalized experience?

Register for free